FT.CE.12: Clinical Study on Nasal Congestion

Home / Clinical Studies / FT.CE.12: Clinical Study on Nasal Congestion

FT.CE.12: Clinical Results for Nasal Symptoms in Children

FT.CE.12 is a medical device based on a pH-controlled isotonic saline solution formulated with N-acetylcysteine (NAC) and methylsulfonylmethane (MSM). It was developed to support nasal hygiene, hydrate the nasal mucosa, and help manage secretions associated with nasal congestion.

In March 2026, Gruppo Farmaimpresa conducted a paediatric clinical study on FT.CE.12 involving 20 children aged 3 to 12 years. The study aimed to assess the device’s efficacy and safety in managing nasal and nasopharyngeal symptoms using the SNOT-22 questionnaire (Sino-Nasal Outcome Test-22).

After 16–17 days of treatment, the total SNOT-22 score decreased significantly from 8.16 to 3.37 points (p < 0.001).

The study also found significant improvements in nasal congestion, cough, and postnasal drip, providing preliminary clinical data supporting the use of FT.CE.12 for upper respiratory tract health.

Nasal Congestion in Children: Symptoms and Associated Problems

Nasal congestion in children is common and is often associated with colds, upper respiratory tract infections, and inflammation of the nasal mucosa.

A build-up of secretions and blockage of the nasal passages can make breathing difficult and cause discomfort that interferes with daily activities.

Common symptoms include the following.

  • Nasal obstruction, with difficulty breathing through the nose.
  • Rhinorrhoea, characterised by excessive nasal discharge.
  • Thick mucus that is difficult to clear naturally.
  • Cough, sometimes associated with postnasal drip.
  • Irritation and dryness of the nasal mucosa.
  • Sleep disturbances related to breathing discomfort.

In these situations, nasal hygiene solutions can help mechanically remove secretions and keep the nasal mucosa hydrated.

FT.CE.12 was developed by combining an isotonic saline solution with functional ingredients to support upper respiratory tract health.

FT.CE.12: NAC and MSM Formulation for Nasal Hygiene

FT.CE.12 is a medical device based on a pH-controlled isotonic saline solution containing N-acetylcysteine (NAC) and methylsulfonylmethane (MSM).

The formulation is designed to help cleanse the nasal passages and manage secretions associated with congestion and rhinorrhoea.

The main ingredients serve complementary functions.

  • N-acetylcysteine (NAC) has mucolytic properties and is used to help thin secretions.
  • Methylsulfonylmethane (MSM) is included in the formulation to support nasal mucosal health.
  • Sodium chloride in isotonic solution helps hydrate and mechanically cleanse the nasal passages.

FT.CE.12 Clinical Study: Methodology and Paediatric Population

The FT.CE.12 clinical study assessed changes in nasal and nasopharyngeal symptoms in children who received the treatment.

The study used a single-arm, uncontrolled, pre–post design, comparing patients’ symptoms before and after treatment.

The study enrolled 20 children aged 3 to 12 years, with a median age of 5 years.

Assessments were carried out at two time points.

  • T0 (baseline) before treatment began.
  • T1 (follow-up) after 16–17 days of treatment.

Efficacy was assessed using the SNOT-22 (Sino-Nasal Outcome Test-22), a 22-item clinical questionnaire that measures the severity of sinonasal symptoms and their impact on quality of life. Each item is scored from 0 to 5. Higher scores indicate more severe symptoms, and a decrease in score indicates improvement.

Study Results: Significant Reduction in SNOT-22 Score

The study’s primary endpoint was the change in total SNOT-22 score between T0 and T1.

The study reported the following results.

  • Mean SNOT-22 score at T0 — 8.16 ± 3.13 points.
  • Mean SNOT-22 score at T1 — 3.37 ± 3.18 points.
  • Mean reduction — 4.79 ± 2.90 points.
  • Statistical significance — p < 0.001.

The reduction was approximately 58.7% of the mean baseline score, indicating an overall improvement in the symptoms assessed by the questionnaire.

The analysis of individual scores also found that 95% of patients had a lower SNOT-22 score at follow-up, and 74% had a reduction of more than 50% from baseline.

These findings suggest an association between treatment with FT.CE.12 and improvement in nasal and nasopharyngeal symptoms in the children studied.

FT.CE.12 Clinical Chart: SNOT-22 Scores at T0 and T1

The chart shows a clear decrease in the SNOT-22 score between baseline and follow-up.

The mean score fell from 8.16 points at T0 to 3.37 points at T1, a mean difference of 4.79 points.

The bars represent mean scores at the two assessment points, and the vertical lines show the variability of the results.

The p-value of less than 0.001 indicates that the observed difference was statistically significant.

The decrease in score suggests an overall improvement in patient-reported symptoms. Without a control group, the study could not determine how much of the observed improvement was attributable to the device.

Nasal Congestion, Cough, and Postnasal Drip: Clinical Results

In addition to the decrease in the total SNOT-22 score, the FT.CE.12 clinical study found statistically significant improvements in three main symptoms: nasal congestion, cough, and postnasal drip.

After 16–17 days of treatment, the relative reduction in symptom frequency was 60% for nasal congestion, 62.5% for cough, and 46.2% for postnasal drip.

The findings suggest an improvement in nasal and nasopharyngeal symptoms in the children studied, providing preliminary clinical data supporting the use of FT.CE.12 for nasal hygiene and upper respiratory tract health.

FT.CE.12: Ready-to-Market and Private Label Medical Device

Are you looking for a paediatric nasal hygiene medical device that is ready to market or can be customised for private label?

FT.CE.12 is an isotonic nasal solution containing N-acetylcysteine (NAC) and methylsulfonylmethane (MSM). It offers pharmaceutical companies and distributors an opportunity to expand their respiratory product portfolios.

Gruppo Farmaimpresa offers FT.CE.12 as a ready-to-market or private label solution, with supporting clinical data and customisation options for your market.

To explore partnership opportunities, see Farmaimpresa’s services for medical device manufacturing and product development and clinical studies.

Contact us

Share:

More Posts:

Send Us A Message

Subscribe to our Newsletter